

Low interleukin-10 release after *ex vivo* stimulation of whole blood is associated with persistent organ dysfunction in sepsis: a prospective observational study

Nicolas NESSELER, MD, PhD ^{1,2,3,4}, Corinne MARTIN-CHOULY, PharmD, PhD ^{2,5},
Harmonie PERRICHET, MD ^{1,2}, James T. ROSS, MD ⁶, Chloé ROUSSEAU, MSc ⁴,
Pratik SINHA MD, PhD⁷, Sonia ISSLAME, MD ¹, Elodie MASSERET, MD ¹, Yannick
MALLÉDANT, MD ^{1,2,3}, Yoann LAUNEY, MD, PhD ^{1,2,3}, Philippe SEGUIN MD, PhD^{1,2,3,4}

¹Intensive Care Unit, Anaesthesia and Critical Care Department, Pontchaillou, University Hospital of Rennes, France

²Rennes 1 University, Rennes, France

³Inserm, UMR 1214 NuMeCan, Pontchaillou, University Hospital of Rennes, , France

⁴Clinical Investigation Centre, INSERM unit 1414, Pontchaillou, University Hospital of Rennes, France

⁵Inserm, UMR 1085 IRSET, Research Institute for Environmental and Occupational Health, Rennes, France

⁶Department of Surgery, University of California, San Francisco, USA

⁷Department of Medicine and Anesthesia, Division of Pulmonary and Critical Care, University of California, San Francisco, USA

Please send correspondence and requests for reprints to:

Dr. Nessler Nicolas, Hôpital Pontchaillou, Pôle Anesthésie, SAMU, Urgences, Réanimations, Médecine Interne et Gériatrie (ASUR-MIG), 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France.

Tel.: 33.2.99.28.42.46; Fax: 33.2.99.28.24.21; e-mail: nicolas.nessler@chu-rennes.fr

Preliminary data for this study were presented as a poster presentation at the International Symposium of Intensive Care and Emergency Medicine (ISICEM), 20-23 march 2018, Brussels, Belgium.

ACCEPTED MANUSCRIPT

Abstract:

Background: Sepsis profoundly alters immune homeostasis. Cytokine release after whole blood lipopolysaccharide (LPS)-stimulation reflects cell function across multiple immune cell classes and represents the immune response to LPS. The main goal of this study was to evaluate the prognostic value of *ex vivo* stimulation of whole blood with LPS in sepsis.

Methods: Blood was drawn on day 1 and day 7 after admission, and stimulated *ex vivo* with LPS. Tumour necrosis factor (TNF)- α , interleukin (IL)-1 β , IL-6 and IL-10 were measured with and without stimulation. Our primary outcome measure was the persistence of at least one organ dysfunction at day 7. Organ dysfunction was defined according to the SOFA components by a score ≥ 2 .

Results: Forty-nine patients with sepsis from a 21-bed intensive care unit, and 23 healthy volunteers were enrolled. The blood of septic patients was less responsive to *ex vivo* stimulation with LPS than that of healthy controls at day 1 and 7, as demonstrated by lower TNF- α , IL-1 β , IL-6 and IL-10 release. Persistent organ dysfunction was more frequent in patients with lower IL-10 release at day 1 but such an association was not found for pro-inflammatory cytokines. A persistent low IL-10 release at day 7 was also associated with persistent organ dysfunction.

Conclusion: These data suggest that the capacity to produce IL-10 in response to whole blood *ex vivo* stimulation early in sepsis, as well as persistent low IL-10 response over time, may help in prognostication and patient stratification. These results will need to be confirmed in future studies.

Keywords: prognosis; immunosuppression; SOFA score; lipopolysaccharide; endotoxin; cytokines.

ACCEPTED MANUSCRIPT

1. Introduction

Immune dysregulation is now a well-recognised phenomenon in Sepsis [1,2]. Improvements in critical care have increased the number of patients who survive the initial hyper-inflammatory phase of sepsis, but also increased the frequency of a chronic critical illness named persistent inflammation, immunosuppression and catabolism syndrome (PICS). PICS has been associated with prolonged intensive care unit (ICU) stays, moderate organ dysfunction, secondary infection, requirement for life support and protein catabolism [3]. Several biomarkers of immunosuppression in sepsis have been proposed to identify the subset of these patients who might benefit from immune therapies [4,5]. The most studied of these have been human leukocyte antigen (HLA)-DR expression on monocytes, and Tumour Necrosis Factor (TNF)- α release in whole blood lipopolysaccharide (LPS)-stimulation assays. Indeed, both decreased HLA-DR expression and decreased release of TNF- α after *ex-vivo* whole blood LPS-stimulation are associated with higher morbidity and mortality in critically ill patients [5-11]. While cell surface HLA-DR expression in monocytes may be considered a phenotypic marker of sepsis severity, cytokine release after whole blood LPS-stimulation reflects cell function across multiple immune cell classes, and represents the immune response to LPS [12,13]. *Ex vivo* whole blood LPS-stimulated TNF- α release has been evaluated as a prognostic marker in critically ill patients in a variety of clinical situations, including sepsis patients, and with a range of clinical endpoints [5,6,10,11,14-19]. Although several authors have studied the release of other cytokines, such as interleukin (IL)-1 β , IL-6, or IL-10, after *ex vivo* whole blood LPS stimulation in sepsis [20-23], few have examined the prognostic value of the release of these cytokines in septic patients after *ex vivo* whole blood LPS

stimulation [14,16,17]. We aim, therefore, to examine the prognostic value of release of TNF- α , IL-1 β , IL-6, and IL-10 after LPS whole blood stimulation measured within the 24 hours and one week after admission in ICU in patients with severe sepsis and septic shock.

ACCEPTED MANUSCRIPT

2. Materials and methods

This prospective observational pilot study was performed between November 2012 and September 2014 in a 21-bed ICU at the University Hospital of Rennes (France). The study was approved by the local institutional ethics committee on June 12, 2012 (Comité d'éthique, Centre Hospitalier Universitaire de Rennes, avis n°12-23, Chairperson: Dr Vincent MOREL) and informed consent was obtained from all participants or their next of kin.

2.1. Study population

Adults patients admitted in the ICU with a first episode of severe sepsis or septic shock were eligible. Severe sepsis and septic shock were defined based on the criteria proposed by the American College of Chest Physician/Society of Critical Care Consensus Conference Committee [24]. Patients who were pregnant or lactating, receiving immunosuppressive drugs, or who had a history of hematologic malignancy were excluded.

2.2. Healthy control

Twenty-three healthy volunteers without medical history were recruited (mean age 33 years, sex ratio M/F 0.9) and informed consent was obtained from all participants.

2.3. Blood samples and ex vivo LPS-stimulation

For each patient, 15 mL of whole blood were collected in heparin-tubes within the first 24 hours of ICU admission (day 1), and then 7 days after ICU admission (day 7) if the patient was still in the study hospital. Within one hour of collection, blood was aliquoted in 96-well microplates under sterile conditions and incubated for 30 minutes at 37°C in an atmosphere of 5% CO₂ and 95% air [25]. At the end of the incubation period, LPS from *Escherichia Coli* O55:B5 (product number L2880, Sigma-Aldrich)

was added in stimulated wells at 10 µg/mL, whereas un-stimulated wells received a sterile saline vehicle only (NaCl 0.9%). After 24h incubation, the plasma supernatants were gently transferred in polypropylene micro tubes and stored at -80°C until cytokine assay.

2.4. Cytokine assay

The concentrations of TNF- α , IL-1 β , IL-6 and IL-10 were determined via enzyme linked-immunosorbent assay (ELISA) according to the manufacturer instructions (Bio-Techne, R&D systems, France). A standard concentration-response curve was run on each microplate to allow determination of cytokine levels in samples. Cytokine concentrations in each sample were determined using an automatic plate reader associated with Genesis software (LabSystems Spectrophotometer, Cambridge, UK) and data were expressed in pg/mL.

2.5. Data collection

The following data were collected: age, sex, ICU admission characteristics, comorbidities and overall severity of pre-existing underlying disease based on McCabe's classification [26], information regarding the site, source and type of initial infection, presence of vasopressors infusion, mechanical ventilation and renal replacement therapy, delay between hypotension and first antimicrobial therapy, use of low-dose corticosteroids, acquisition of health-care associated infection in ICU, length of ICU and study hospital stay, 28- and 90-day mortality. The severity of the illness was assessed within 24 hours of ICU admission using the Simplified Acute Physiology Score (SAPS) II. The Sequential Organ Failure Assessment (SOFA) score and white blood cell count were assessed within the first 24 h and 7 days after the admission in ICU if the patient was still in the study hospital.

2.6. Outcome definitions

Our primary outcome measure was the persistence of at least one organ dysfunction at day 7. Organ dysfunction or failure was defined according to the SOFA components by a score ≥ 2 . The secondary outcomes were health-care associated infection in the ICU according to the Centres for Disease Control and Prevention definitions (central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia and surgical site infections), and 28- and 90-day mortality.

2.7. Study design

For each patient, the cytokine concentration after LPS stimulation was compared to the concentration in samples incubated without LPS (baseline), and expressed as a ratio (stimulated/baseline). A ratio above 1.5 at day 1 and day 7 was chosen as an arbitrary cut-off point, to reflect a potentially preserved response after LPS-stimulation.

First, the cytokine variations after stimulation were compared between septic patients and healthy controls. Then, the proportion of patients with persistent organ dysfunction at day 7 was compared between patients below and above the 1.5 ratio for each cytokine at day 1. Finally, the relationship between organ dysfunction and the temporal evolution of cytokine release after whole blood LPS-stimulation was studied. For this final analysis, only the patients with a ratio below 1.5 at day 1, for a given cytokine were considered. For each of these groups, the proportion of patients with persistent organ dysfunction at day 7 was compared between patients who recovered a ratio above 1.5 at day 7 and those who did not.

2.8. Statistical Analysis

All statistical analysis was performed using PRISM 7 (GraphPad Software, La Jolla, Ca, USA). Quantitative data were expressed as median and interquartile ranges (IQR), while categorical data were expressed as absolute values and percentages. Quantitative data were compared using Mann-Whitney U test. Categorical data were compared using chi-square tests or Fisher's exact test in case of non-parametric data. A two-sided p-value < 0.05 was considered statistically significant.

ACCEPTED MANUSCRIPT

3. Results

3.1. Patient characteristics

A total of 49 patients were enrolled in the study, including 37 patients with septic shock (76%). Thirty-one patients (63%) were mechanically ventilated. The origin of sepsis was abdominal in 61% of the cases. The rate of appropriate first antimicrobial therapy was 89% and the median duration between hypotension and initiation of an effective antimicrobial therapy was 0 (0-30) minutes. Other patient characteristics are displayed in table 1.

3.2. Cytokine release

Median concentration of cytokine release with and without LPS-stimulation at day 1 and day 7, in septic patients and healthy volunteers, are displayed in table 2.

3.3. Comparison of the cytokine release after whole blood LPS-stimulation in septic patient with those in healthy controls

At day 1 and day 7, the ratio of cytokine release after whole blood LPS-stimulation to cytokine release at baseline in septic patients were significantly lower than the same ratio in healthy controls (Figure 1).

When considering only patients with samples available at day 1 and at day 7 (n=35 except for IL-6 n=34), a significant increase was seen in this ratio between day 1 and day 7 for IL-1 β , IL-6 and IL-10 but not for TNF- α (Figure 2).

3.4. Persistent organ dysfunction at day 7

Considering IL-10 release, a significantly higher proportion of patients with a ratio below 1.5 at day 1 was found to have persistent organ dysfunction (SOFA score ≥ 2) at day 7 than patients with a ratio above 1.5 (13/24 vs 4/20 respectively, $p=0.03$). However, the proportion of patients with persistent organ dysfunction at day 7 was not significantly different between patients with a ratio below and above 1.5 for IL-1 β (8/19 vs 9/27 respectively, $p >0.99$), IL-6 (9/21 vs 7/24, $p=0.12$) or TNF- α (11/27 vs 6/18, $p=0.38$) release at day 1. Similarly, when considering cytokine release at day 7, there was no significant relationship between patients with a ratio below and above 1.5 and organ dysfunction for any of the measured cytokines, including IL-10.

3.5. Secondary outcomes

Only three patients (6%) died within 28 days, five patients (10%) died within 90 days, and five patients (10%) developed healthcare-associated infection in the ICU. These outcomes were less common than expected, precluding further analysis.

3.6. Relationship between persistent organ failure at day 7 and the temporal evolution of cytokine release after whole blood LPS-stimulation (figure 3)

When considering only IL-10 release, patients whose ratio was below 1.5 at day 1 and increased above 1.5 at day 7 were significantly less likely to have persistent organ dysfunction than patients who did not recover IL-10 release at day 7 (6/14 vs 5/5, respectively $p=0.045$). However, no significant difference in organ dysfunction was found between patients whose ratio was below 1.5 at day 1 and increased above 1.5 at day 7 for IL-6 (3/10 vs 3/4, respectively $p=0.25$), IL-1 β (5/10 vs 2/3 respectively, $p >0.99$) or TNF- α (3/9 vs 8/13 respectively, $p=0.39$).

4. Discussion

We observed a significant and prolonged reduction of TNF- α , IL-1 β , IL-6 and IL-10 release after whole blood LPS-stimulation in septic patients compared to healthy controls. This reduction in TNF- α , IL-1 β , IL-6 and IL-10 release likely reflects the well-described phenomenon of LPS tolerance or immunoparalysis, in which circulating leukocytes in septic patients have a diminished ability to release additional cytokines [22,27]. We also observed that patients with low IL-10 release after LPS stimulation at day 1 had a higher rate of persistent organ dysfunction. Moreover, persistently low IL-10 release was associated with higher proportion of organ dysfunction at day 7. The same kind of association was not observed with the other cytokines.

The data available concerning the release of IL-10 after whole blood LPS-stimulation in septic patients are scarce and contradictory. While Marchant et al. found a decrease in IL-10 release in 10 patients with septic shock compared to healthy controls, Rigato and Salomao did not observe any differences in IL-10 release in 20 septic patients (including 15 with septic shock) compared to healthy controls [20,21]. Four hours after experimental endotoxemia in healthy human volunteers, Kox et al. reported a 45% drop in peak IL-10 release after *ex vivo* LPS stimulation [28]. Other authors have reported that, while peripheral blood mononuclear cells (PBMCs) in septic patients released less IL-10 than in healthy controls after LPS stimulation, IL-10 release from the monocytes of septic patients after LPS stimulation was higher than in healthy controls [29,30]. Finally, *ex vivo* stimulation of whole blood from septic patients, with intact *Escherichia coli*, leads to a depressed IL-10 release compared to healthy controls, but stimulation with intact *Pseudomonas aeruginosa* does not [21,23].

It may be that a decreasing ability to release IL-10 in whole blood in response to *ex vivo* stimulation is the result of significant ongoing IL-10 production *in vivo*, and may reflect immunosuppression. This explanation is consistent with previous studies, which found that elevated plasma IL-10 concentrations were associated with mortality in severe sepsis and septic shock [31-34]. Elevated plasma IL-10 was also found to be associated with ICU acquired infections in severe sepsis and septic shock, although other authors did not find any associations [34,35]. In one study, IL-10 release after LPS-stimulation in PBMCs was found to be higher in non-surviving septic patients, the opposite of the pattern that we observed [30]. This difference may be explained by our use of a whole blood stimulation assay, which allows the evaluation not only of PMBCs functionality, but also of other immune cells including granulocytes and platelets [36,37]. Furthermore, the use of whole blood maintains interactions between cellular elements that are required for cell viability, and avoids the potential influence of artificial medium on isolated cells [37].

We did not find any association between inflammatory cytokine release after whole blood LPS-stimulation at day 1 and persistent organ dysfunction. Several studies have previously evaluated TNF- α release after whole blood LPS-stimulation and outcomes in septic patients with contradictory results. Ploder et al. reported that TNF- α release after *ex vivo* stimulation in 19 patients with polytrauma and sepsis was lower in non-survivors than in survivors [15]. Similarly, in 52 critically ill children with Influenza, lower TNF- α release upon *ex vivo* stimulation within 72 hours of ICU admission was associated with higher mortality and fewer ICU-free days [10]. Finally lower TNF- α release was found to be associated with persistent organ dysfunction in 102 septic children as well as in 24 septic adults [18,19]. In contrast, in 83 adults with severe sepsis, TNF- α release at several time points was not found associated with

survival or development of secondary infection [6]. Similarly, no association was found between TNF- α , IL-6 or IL-1 β release after whole blood LPS-stimulation in another population of 73 critically ill patient (including 47 septic patients) and subsequent development of ICU-acquired infections [17]. These discrepancies could be explained in part by the lack of standardisation of LPS-induced cytokine production assays. Indeed, TNF- α release was found to be highly dependent on the source and concentration of LPS, duration and temperature of incubation, anticoagulation, and sample dilution [38]. As a result, increased standardisation of LPS stimulation assays is urgently required in order to improve the external validity of studies in this area. In our study, although the stimulation protocol was based on a previous study in COPD patients [39], LPS concentration was higher and incubation time longer than that often reported in studies performing whole blood LPS-stimulation in septic patients. This study is, to the best of our knowledge, the first to report an association between low release of IL-10 after *ex vivo* whole blood LPS-stimulation and persistent organ failure in a prospective cohort of severe sepsis patients. Moreover, the cytokine release was evaluated at two different time points to better reflect the dynamic process of inflammation in sepsis. However, several limitations must be underlined. First, as discussed above, our LPS-stimulation protocol differed in several points from the protocols generally used in septic patients, limiting the comparability of our data. Also, our septic population was older than the healthy volunteers, so the comparison could not be age-matched. This is relevant because older age is associated with a state of chronic inflammation, and impaired production of pro-inflammatory cytokines in response to lipopolysaccharide stimulation has been reported in the elderly [40,41]. However, human studies comparing levels of cytokine release between young and older septic patients

remains scarce and the data contradictory [41]. Additionally, our sample size is small, as our work was designed as a pilot study. Also, while our study population was severely ill, with 76% having septic shock, and high median SOFA and SAPS II scores, both the rates of mortality and healthcare associated infections were lower than typically reported [42-46]. These low rates precluded the use of these outcomes as secondary endpoints as previously planned. Moreover, a monocentric design and the enrolment of mainly surgical (80%) patients limit the generalisation of our results. Further studies are needed to confirm our results in a larger and multicentre cohort with a higher ratio of medical patients and with additional endpoints.

5. Conclusion

Early low IL-10 release after *ex vivo* LPS stimulation of whole blood in sepsis, as well as persistent low IL-10 response over time, may be associated with persistent organ dysfunction. While these results will need to be confirmed in future studies, they do highlight the potential role of early IL-10 release and evolution of IL-10 release after *ex vivo* LPS stimulation of whole blood in sepsis as both a potential prognostic marker, and a potential means to stratify patients in clinical trials of immunomodulatory therapeutics.

Ethical statement

The study was approved by the local institutional ethics committee on June 12, 2012 (Comité d'éthique, Centre Hospitalier Universitaire de Rennes, avis n°12-23, Chairperson: Dr Vincent MOREL) and informed consent was obtained from all participants or their next of kin.

Declarations of interest

The authors declare that there is no conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions

NN and CMC contributed to the study concept and design. NN, CMC, HP, JTR, PSi, YL, SI, EM, PS and YM contributed to the acquisition, analysis, or interpretation of data for the work. CR and NN performed the statistical analysis. NN, CMC, HP, JTR, PS and YM drafted the manuscript, which was revised for important intellectual content by PSi, YL, SI and EM. All authors read and approved the final manuscript.

References

- [1] Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis* 2013;13:260–8. doi:10.1016/S1473-3099(13)70001-X.
- [2] van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. *Nat Rev Immunol* 2017;17:407–20. doi:10.1038/nri.2017.36.
- [3] Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. *J Trauma Acute Care Surg* 2012;72:1491–501. doi:10.1097/TA.0b013e318256e000.
- [4] Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte–Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression. *Am J Respir Crit Care Med* 2009;180:640–8. doi:10.1164/rccm.200903-0363OC.
- [5] Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk H-D, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. *Intensive Care Med* 2010;37:525–32. doi:10.1007/s00134-010-2088-x.
- [6] Drewry AM, Ablordeppey EA, Murray ET, Beiter ER, Walton AH, Hall MW, et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. *Critical Care* 2016;20:260–10. doi:10.1186/s13054-016-1505-0.
- [7] Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard A-L, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. *Intensive Care Med* 2006;32:1175–83. doi:10.1007/s00134-006-0204-8.
- [8] Lukaszewicz A-C, Griénay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. *Crit Care Med* 2009;37:2746–52. doi:10.1097/CCM.0b013e3181ab858a.
- [9] Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohé J, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. *Intensive Care Med* 2010;36:1859–66. doi:10.1007/s00134-010-1962-x.
- [10] Hall MW, Geyer SM, Guo C-Y, Panoskaltis-Mortari A, Jouvét P, Ferdinands J, et al. Innate Immune Function and Mortality in Critically Ill Children With Influenza. *Crit Care Med* 2013;41:224–36. doi:10.1097/CCM.0b013e318267633c.
- [11] Muszynski JA, Nofziger R, Greathouse K, Nateri J, Hanson-Huber L, Steele L, et al. Innate Immune Function Predicts the Development of Nosocomial Infection in Critically Injured Children. *Shock* 2014;42:313–21. doi:10.1097/SHK.0000000000000217.
- [12] Winkler MS, Rissiek A, Prießler M, Schwedhelm E, Robbe L, Bauer A, et al. Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNF α response: A diagnostic tool for immunosuppression? *PLoS ONE* 2017;12:e0182427–14. doi:10.1371/journal.pone.0182427.

- [13] Duffy D, Rouilly V, Libri V, Hasan M, Beitz B, David M, et al. Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli. *Immuni* 2014;40:436–50. doi:10.1016/j.immuni.2014.03.002.
- [14] Heagy W, Nieman K, Hansen C, Cohen M, Danielson D, West MA. Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. *Surg Infect (Larchmt)* 2003;4:171–80. doi:10.1089/109629603766956960.
- [15] Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. *Shock* 2006;25:129–34. doi:10.1097/01.shk.0000191379.62897.1d.
- [16] Allen ML, Hoschitzky JA, Peters MJ, Elliott M, Goldman A, James I, et al. Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. *Crit Care Med* 2006;34:2658–65. doi:10.1097/01.CCM.0000240243.28129.36.
- [17] van Vught LA, Wiewel MA, Hoogendijk AJ, Scicluna BP, Belkasim-Bohoudi H, Horn J, et al. Reduced Responsiveness of Blood Leukocytes to Lipopolysaccharide Does not Predict Nosocomial Infections in Critically Ill Patients. *Shock* 2015;44:110–4. doi:10.1097/SHK.0000000000000391.
- [18] Muszynski JA, Nofziger R, Moore-Clingenpeel M, Greathouse K, Anglim L, Steele L, et al. Early Immune Function and Duration of Organ Dysfunction in Critically Ill Septic Children. *Am J Respir Crit Care Med* 2018:rccm.201710–2006OC. doi:10.1164/rccm.201710-2006OC.
- [19] Maddux AB, Hiller TD, Overdier KH, Pyle LL, Douglas IS. Innate Immune Function and Organ Failure Recovery in Adults With Sepsis. *J Intensive Care Med* 2017;11:885066617701903. doi:10.1177/0885066617701903.
- [20] Marchant A, Alegre ML, Hakim A, Piérard G, Marécaux G, Friedman G, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. *Journal of Clinical Immunology* 1995;15:266–73. doi:10.1007/BF01540884.
- [21] Rigato O, Salomao R. Impaired Production of Interferon-gamma and Tumor Necrosis Factor-alpha but not of Interleukin 10 in Whole Blood of Patients with Sepsis. *Shock* 2003;19:113–6. doi:10.1097/00024382-200302000-00004.
- [22] Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. *Blood* 1995;85:1341–7.
- [23] Haupt W, Zirngibl H, Riese J, Stehr A, Linde HJ, Hohenberger W. Depression of Tumor Necrosis Factor- α , Interleukin-6, and Interleukin-10 Production: A Reaction to the Initial Systemic Hyperactivation in Septic Shock. *Journal of Investigative Surgery* 2009;10:349–55. doi:10.3109/08941939709099598.
- [24] Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. *American College of Chest Physicians/Society of Critical Care Medicine. Chest*, vol. 101, 1992, pp. 1644–55.
- [25] Jouneau S, Bonizec M, Belleguic C, Desrues B, Brinchault G, Galaine J, et al. Anti-Inflammatory Effect of Fluvastatin on IL-8 Production Induced by

- Pseudomonas aeruginosa* and *Aspergillus fumigatus* Antigens in Cystic Fibrosis. *PLoS ONE* 2011;6:e22655–8. doi:10.1371/journal.pone.0022655.
- [26] McCABE WR. Gram-Negative Bacteremia. *Arch Intern Med* 1962;110:847. doi:10.1001/archinte.1962.03620240029006.
- [27] Cavaillon J-M, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. *Crit Care* 2006;10:233. doi:10.1186/cc5055.
- [28] Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, et al. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia*. *Crit Care Med* 2011;39:1866–70. doi:10.1097/CCM.0b013e3182190d5d.
- [29] Adib-Conquy M, Adrie C, Fitting C, Gattolliat O, Beyaert R, Cavaillon J-M. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients*. *Crit Care Med* 2006;34:2377–85. doi:10.1097/01.CCM.0000233875.93866.88.
- [30] Stanilova SA, Karakolev ZT, Dimov GS, Dobrova ZG, Miteva LD, Slavov ES, et al. High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. *Intensive Care Med* 2005;31:401–7. doi:10.1007/s00134-005-2575-7.
- [31] Monneret G, Finck M-E, Venet F, Debard A-L, Bohé J, Bienvenu J, et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. *Immunology Letters* 2004;95:193–8. doi:10.1016/j.imlet.2004.07.009.
- [32] Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. *Arch Intern Med* 2007;167:1655–63. doi:10.1001/archinte.167.15.1655.
- [33] Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC. Relationship Between Alternative Resuscitation Strategies, Host Response and Injury Biomarkers, and Outcome in Septic Shock. *Crit Care Med* 2017;45:438–45. doi:10.1097/CCM.0000000000002206.
- [34] Frencken JF, van Vught LA, Peelen LM, Ong DSY, Klein Klouwenberg PMC, Horn J, et al. An Unbalanced Inflammatory Cytokine Response Is Not Associated With Mortality Following Sepsis. *Crit Care Med* 2017;45:e493–9. doi:10.1097/CCM.0000000000002292.
- [35] Gomez HG, Gonzalez SM, Londoño JM, Hoyos NA, Niño CD, Leon AL, et al. Immunological Characterization of Compensatory Anti-Inflammatory Response Syndrome in Patients With Severe Sepsis. *Crit Care Med* 2014;42:771–80. doi:10.1097/CCM.0000000000000100.
- [36] Chen J, Bruns AH, Donnelly HK, Wunderink RG. Comparative in vitro stimulation with lipopolysaccharide to study TNF α gene expression in fresh whole blood, fresh and frozen peripheral blood mononuclear cells. *Journal of Immunological Methods* 2010;357:33–7. doi:10.1016/j.jim.2010.03.006.
- [37] Thurm CW, Halsey JF. Measurement of cytokine production using whole blood. *Curr Protoc Immunol* 2005;Chapter 7:Unit7.18B. doi:10.1002/0471142735.im0718bs66.
- [38] Segre E, Fullerton JN. Stimulated Whole Blood Cytokine Release as a Biomarker of Immunosuppression in the Critically Ill. *Shock* 2016;45:490–4. doi:10.1097/SHK.0000000000000557.

- [39] Ouagued M, Martin-Chouly CAE, Brinchault G, Leportier-Comoy C, Depincé A, Bertrand C, et al. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF- α production in whole blood from COPD patients. *Pulm Pharmacol Ther* 2005;18:49–54. doi:10.1016/j.pupt.2004.09.031.
- [40] Bruunsgaard H, Pedersen AN, Schroll M, Skinhoj P, Pedersen BK. Impaired production of proinflammatory cytokines in response to lipopolysaccharide (LPS) stimulation in elderly humans. *Clin Exp Immunol* 1999;118:235–41.
- [41] Starr ME, Saito H. Sepsis in old age: review of human and animal studies. *A&D* 2014;5:126–36. doi:10.14336/AD.2014.0500126.
- [42] Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. *Jama* 2014;311:1308–16. doi:10.1001/jama.2014.2637.
- [43] Vincent J-L, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. *Lancet Respir Med* 2014;2:380–6. doi:10.1016/S2213-2600(14)70061-X.
- [44] Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. *Jama* 2017;318:1241–9. doi:10.1001/jama.2017.13836.
- [45] van Vught LA, Klein Klouwenberg PMC, Spitoni C, Scicluna BP, Wiewel MA, Horn J, et al. Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis. *Jama* 2016;315:1469–11. doi:10.1001/jama.2016.2691.
- [46] Drewry AM, Ablordeppey EA, Murray ET, Beiter ER, Walton AH, Hall MW, et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor α production as outcome predictors in severe sepsis: a prospective observational study. *Critical Care* 2016;20:260–10. doi:10.1186/s13054-016-1505-0.

Figure legends

Figure 1

Comparison of the ratio of cytokine release after whole blood lipopolysaccharide-stimulation to cytokine release at baseline at day 1 and day 7 between septic patients and healthy controls, **A**: Tumor Necrosis Factor(TNF)- α (n=48 septic patients and 23 healthy controls), **B**: Interleukin (IL)-1 β (n=49 and 23 respectively), **C**: IL-6(n=48 and 22 respectively) and **D**: IL-10 (n=47 and 23 respectively), Data presented as box-plots with minimum to maximum value on a log-scale, Mann-Whitney U test **** $P < 0.0001$.




Figure 2

Evolution of the ratio of cytokine release after whole blood lipopolysaccharide-stimulation to cytokine release at baseline between day 1 and day 7 (n=35, except IL6 n=34), **A**: Tumor Necrosis Factor(TNF)- α **B**: Interleukin (IL)-1 β , **C**: IL-6 and **D**: IL-10, Median with interquartile range, Mann-Whitney U test * $P=0.03$, ** $P=0.01$ and *** $P=0.0005$.







Table 1 Patient Characteristics (n=49)

Age, years, median (IQR)	64 (54-70)
Gender, (male) n (%)	29 (59)
MacCabe, n (%)	
A	23 (47)
B	23 (47)
C	3 (6)
Type of admission, n (%)	
Medical	10 (20)
Surgical Emergency	35 (71)
Surgical Scheduled	4 (9)
Septic Shock, n (%)	37 (76)
Mechanical Ventilation, n (%)	31 (63)
Renal Replacement Therapy, n (%)	7 (14)
Low-Dose Corticosteroids use, n (%)	8 (16)
Site of Initial Infection, n (%)	
Intra-Abdominal	30 (61)
Urinary Tract	7 (15)
Lung	6 (12)
Others	6 (12)
Type of Infection, n (%)	
Gram-positive	30 (61)
Gram-negative	25 (51)
Fungi	6 (12)
Source of Initial Infection, n (%)	
Community-acquired	23 (47)
Health-care associated	26 (53)
Healthcare Associated Secondary Infection ICU-Acquired, n (%)	5 (10)
SSI	3
VAP	2
SAPS II, median (IQR)	44 (35-56)
SOFA score, median (IQR)	
Day 1	7 (5-8)
Day 7 n=46	1 (0-3)
White Blood Cells day 1, 10⁹/L, median (IQR) n=46	15.9 (10.8-20.8)
White Blood Cells day 7, 10⁹/L, median (IQR) n=35	14.7 (10.7-18.4)
ICU Free-Days at Day 28, median (IQR)	22 (16-25)
Hospital Mortality, n (%)	2 (4)
Day 90 Mortality, n (%)	5 (10)

ICU=Intensive Care Unit, SAPS= Simplified Acute Physiology Score, SOFA= Sequential Organ Failure Assessment, SSI= Surgical Site Infection, VAP=Ventilator-Associated Pneumonia

Table 2 Median concentrations (pg/mL) of cytokine release in whole blood without (baseline) and with LPS stimulation in septic patients at day 1 and day 7, and in healthy volunteers.

	Day 1		Day 7		Healthy Volunteers	
	Baseline, n=49	LPS	Baseline, n=35	LPS	Baseline, n=23	LPS
TNFα	44.57 (5.50-204.91), n=48	129.26 (20.09-391.77)	127.77 (5.50-223.76)	305.77 (71.10-851.41)	5.50 (5.50-122.25)	2,461.60 (1,690.80- 6,525.80)
IL1β	2.03 (1.00-37.84)	50.80 (1.00-251.93)	136.70 (11.59-369.55)	904.02 (341.09-1,672.65)	1.00 (1.00-103.45)	3,998.20 (2,637.00- 5,883.55)
IL6	1,805.35 (404.9-8,326.23), n=48	4,440.10 (1,284.15- 9,839.04)	4,868.25 (1,230.52- 8,734.45)	12,194.90 (7,039.39- 23,868.50)	9.05 (0.70-311.55), n=22	23,460.80 (1,6330.23- 35,519.53)
IL10	119.01 (43.43-373.88), n=47	222.51 (98.47-452.47)	136.42 (52.99-271.14)	451.27 (204.64-626.72)	3.90 (3.90-140.80)	1,000.20 (685.10-1,606.30)

Data are presented as median (IQR). IL=Interleukin, LPS=Lipopolysaccharide, TNF= Tumor Necrosis Factor.